J. Arends

517 total citations
8 papers, 251 citations indexed

About

J. Arends is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, J. Arends has authored 8 papers receiving a total of 251 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 1 paper in Surgery. Recurrent topics in J. Arends's work include Colorectal Cancer Treatments and Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers) and MRI in cancer diagnosis (1 paper). J. Arends is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers) and MRI in cancer diagnosis (1 paper). J. Arends collaborates with scholars based in Netherlands, Germany and Australia. J. Arends's co-authors include R. J. L. F. Loffeld, K. Mross, Annette Frost, Esther Hauben, Jan P. Vandenbroucke, Pancras C.W. Hogendoorn, E. Van Marck, Ulrike Fasol, Martin Büchert and Ulrike Fiedler and has published in prestigious journals such as American Journal of Clinical Nutrition, Annals of Oncology and European Journal of Human Genetics.

In The Last Decade

J. Arends

8 papers receiving 242 citations

Peers

J. Arends

ONCOL

MB

PRM

SURGE

BIOMA

Kong Fan-min China

Xiaohui Qian China

Takafumi Hirao Japan

Lisi Peng China

Evangelos Tsiambas Greece

Eun Sung Jun South Korea

Mengwei Wang China

Hank C. Hill United States

Lumin Bo China

Ming Chao China

Kong Fan-min China

J. Arends

64 ×0.8

ONCOL

71 ×0.9

MB

71 ×1.1

PRM

114 ×1.8

SURGE

43 ×0.9

BIOMA

Citations per year, relative to J. Arends J. Arends (= 1×) peers Kong Fan-min

Countries citing papers authored by J. Arends

Since Specialization

Citations

This map shows the geographic impact of J. Arends's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Arends with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Arends more than expected).

Fields of papers citing papers by J. Arends

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Arends. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Arends. The network helps show where J. Arends may publish in the future.

Co-authorship network of co-authors of J. Arends

This figure shows the co-authorship network connecting the top 25 collaborators of J. Arends. A scholar is included among the top collaborators of J. Arends based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Arends. J. Arends is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Orsso, Camila E., J. Arends, M.A.E. de van der Schueren, et al.. (2024). Effects of high-protein supplementation during cancer therapy: a systematic review and meta-analysis. American Journal of Clinical Nutrition. 120(6). 1311–1324. 8 indexed citations

2.

Fasol, Ulrike, Annette Frost, Martin Büchert, et al.. (2011). Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Annals of Oncology. 23(4). 1030–1036. 79 indexed citations

3.

Mross, K., Martin Büchert, Ulrike Fasol, et al.. (2011). A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment - a study of the CESAR central european society for anticancer drug research - EWIV**. 4 indexed citations

4.

Mross, K., Martin Büchert, Ulrike Fasol, et al.. (2011). A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.. PubMed. 49(1). 96–8. 6 indexed citations

5.

Steinbild, Simone, J. Arends, Michael Medinger, et al.. (2007). Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study. Oncology Research and Treatment. 30(12). 629–635. 34 indexed citations

6.

Hauben, Esther, et al.. (2003). Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. European Journal of Human Genetics. 11(8). 611–618. 69 indexed citations

7.

Meyenfeldt, M.F. von, et al.. (1995). [10-year follow-up after surgery for colon cancer: no further mortality from cancer after 7 years].. PubMed. 139(8). 382–8. 3 indexed citations

8.

Loffeld, R. J. L. F., et al.. (1992). Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus.. PubMed. 87(11). 1598–600. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact